Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

December 24, 2013

Primary Completion Date

June 1, 2015

Study Completion Date

August 3, 2016

Conditions
Pancreatic Neoplasms
Interventions
DRUG

nab-paclitaxel

nab-paclitaxel at 125 mg/m\^2, by IV infusion over 30 to 40 minutes (maximum infusion time not to exceed 40 minutes)

DRUG

Gemcitabine

Gemcitabine at 1000 mg/m\^2 IV infusion over 30 to 40 minutes given once weekly for 3 weeks (Days 1, 8 and 15) followed by a week of rest (28 day cycle).

Trial Locations (15)

100039

307 Hospital of Chinese PLA, Beijing

100142

Beijing Cancer Hospital, Beijing, PR

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang

100730

Peking Union Medical College Hospital, Beijing

The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang

100853

Chinese PLA General Hospital, Beijing

150081

Harbin Medical University Tumor Hospital, Harbin, Heilongjiang

200032

Fudan University Shanghai Cancer Center, Shanghai

200080

Shanghai First People's Hospital, Shanghai

210029

Jiangsu Province Hospital The First Hospital affiliated with Nanjing Medical University, Nanjing

215006

Zhejiang Cancer Hospital, Hangzhou

300060

Tianjin Medical University Cancer Institute and Hospital, Tianjin

510060

Sun Yat-sen University Cancer Center, Guangzhou

710032

Xijing Hospital, Xi'an

Unknown

Henan Cancer Hospital, Zhengzhou

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY